The exclusion criteria were other mental illnesses, dementia of any etiology, brain trauma, drug addiction, severe somatic diseases in the stage of decompensation, a history of allergic reactions, or severe multiple hypersensitivities to medications
Randomized, controlled, multicentered, double-blind investigation of injectable poly-L-lactic acid for improving skin quality
Table of Contents Understanding Medicare coverage for GLP-1 therapies How expanded reimbursement changes audience targeting Why pharma media strategies are evolving Future opportunities for healthcare marketers Conclusion Frequently Asked Questions Why Medicare Coverage for GLP-1 Therapies Matters to Healthcare Marketers GLP-1 receptor agonists, including Ozempic, Wegovy, Mounjaro, and Zepbound, have transformed treatment for type 2 diabetes and obesity
doi: 10.1186/s13054-022-04090-1 Liu XW, Wang CD
Herbivore-induced maize leaf volatiles affect attraction and feeding behavior of Spodoptera littoralis caterpillars
What the research shows about GLP-1 medications: According to a study published in the New England Journal of Medicine (STEP-1 trial), participants receiving once-weekly semaglutide 2.4 mg plus lifestyle intervention experienced a mean weight loss of 14.9% from baseline over 68 weeks, compared with 2.4% for placebo plus lifestyle intervention
